The experimental inflammation drug was seen as having 'pipel...
The experimental inflammation drug was seen as having 'pipeline-in-a-product' potential, meaning it could be effective in treating a range of conditions. However, the recent clinical hold by the FDA could significantly impact the development and potential of zelnecirnon.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000174855d9bb2f16.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment